Strategies to procure high-quality core-needle biopsy (CNB) specimens are critical for making basic tissue diagnoses and for ancillary testing. A study at MD Anderson shows the potential of a diagnostic tool called fluorescence confocal digital microscopy (FCM) for rapid and accurate diagnosis.
Results from the study, published in the March 5 issue of JAMA Network Open, demonstrated the utility of next-generation digital microscopy...
An MD Anderson Phase I clinical trial demonstrated that a combination therapy using WNT974, a drug that targets the WNT pathway in cancer,...
Results from two MD Anderson studies demonstrated the significance of combination therapy in follicular lymphoma and chronic lymphoblastic...
The addition of nivolumab to induction chemotherapy with idarubicin and cytarabine is feasible in patients with newly diagnosed acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS), according to findings from a study at The University of Texas MD Anderson Cancer Center.
A study that enrolled 44 patients between August 2015 and June 2018 reported on its findings this month online at The Lancet Haematology. The...
A study at The University of Texas MD Anderson Cancer Center has shed information on a novel oncogenic pathway and points to the use of BET...
Just as a driver’s night vision improves by simply cleaning the headlights, scientists at The University of Texas MD Anderson Cancer Center...
Researchers at MD Anderson Cancer Center have defined a new oncogene for B-cell lymphomas. The cancer-causing gene, known as heterogeneous...
A randomized Phase III clinical trial combining two common chemotherapy agents as a pre-stem cell transplant treatment at The University of...
Whether it is new clinical trials for pediatric cancers or programs designed to increase access to smoking cessation programs for low-income...
Researchers in MD Anderson’s Leukemia department played central roles in the studies of two drugs, glasdegib and venetoclax, approved in November...